Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich.
Clin Infect Dis. 2014 Jan;58(2):285-94. doi: 10.1093/cid/cit694. Epub 2013 Oct 21.
Human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compromise antiretroviral therapy (ART) and thus represents an important public health concern. Typically, sources of TDR remain unknown, but they can be characterized with molecular epidemiologic approaches. We used the highly representative Swiss HIV Cohort Study (SHCS) and linked drug resistance database (SHCS-DRDB) to analyze sources of TDR.
ART-naive men who have sex with men with infection date estimates between 1996 and 2009 were chosen for surveillance of TDR in HIV-1 subtype B (N = 1674), as the SHCS-DRDB contains pre-ART genotypic resistance tests for >69% of this surveillance population. A phylogeny was inferred using pol sequences from surveillance patients and all subtype B sequences from the SHCS-DRDB (6934 additional patients). Potential sources of TDR were identified based on phylogenetic clustering, shared resistance mutations, genetic distance, and estimated infection dates.
One hundred forty of 1674 (8.4%) surveillance patients carried virus with TDR; 86 of 140 (61.4%) were assigned to clusters. Potential sources of TDR were found for 50 of 86 (58.1%) of these patients. ART-naive patients constitute 56 of 66 (84.8%) potential sources and were significantly overrepresented among sources (odds ratio, 6.43 [95% confidence interval, 3.22-12.82]; P < .001). Particularly large transmission clusters were observed for the L90M mutation, and the spread of L90M continued even after the near cessation of antiretroviral use selecting for that mutation. Three clusters showed evidence of reversion of K103N or T215Y/F.
Many individuals harboring viral TDR belonged to transmission clusters with other Swiss patients, indicating substantial domestic transmission of TDR in Switzerland. Most TDR in clusters could be linked to sources, indicating good surveillance of TDR in the SHCS-DRDB. Most TDR sources were ART naive. This, and the presence of long TDR transmission chains, suggests that resistance mutations are frequently transmitted among untreated individuals, highlighting the importance of early diagnosis and treatment.
人类免疫缺陷病毒 1 型(HIV-1)传播的耐药性(TDR)可损害抗逆转录病毒治疗(ART),因此是一个重要的公共卫生关注点。通常,TDR 的来源未知,但可以通过分子流行病学方法来描述。我们利用具有代表性的瑞士艾滋病毒队列研究(SHCS)和相关的耐药数据库(SHCS-DRDB)来分析 TDR 的来源。
选择在 1996 年至 2009 年间感染日期估计的接受 ART 治疗的男男性行为者中的无 ART 治疗的男性进行 HIV-1 亚型 B 的 TDR 监测(N=1674),因为 SHCS-DRDB 包含对该监测人群中 >69%的患者进行的 ART 前基因型耐药检测。从监测患者的 pol 序列和 SHCS-DRDB 中的所有亚型 B 序列(6934 个附加患者)推断出系统发育。根据系统发育聚类、共同耐药突变、遗传距离和估计的感染日期来确定 TDR 的潜在来源。
在 1674 名监测患者中,有 140 名(8.4%)携带具有 TDR 的病毒;140 名中有 86 名(61.4%)被归为聚类。对这些患者中的 50 名(58.1%)患者发现了 TDR 的潜在来源。ART 初治患者构成 66 个潜在来源中的 56 个(84.8%),并且在来源中显著过度代表(比值比,6.43[95%置信区间,3.22-12.82];P<.001)。特别大的传播聚类观察到 L90M 突变,并且在选择该突变的抗逆转录病毒药物的使用几乎停止后,L90M 的传播仍在继续。三个聚类显示 K103N 或 T215Y/F 逆转的证据。
许多携带病毒 TDR 的个体属于与其他瑞士患者的传播聚类,这表明瑞士国内 TDR 的传播相当多。大多数聚类中的 TDR 都可以与来源相关联,这表明 SHCS-DRDB 对 TDR 的监测良好。大多数 TDR 来源是 ART 初治患者。这一点,以及存在较长的 TDR 传播链,表明耐药突变经常在未接受治疗的个体中传播,突出了早期诊断和治疗的重要性。